ClinicalTrials.gg

Program

jaktinib

Also written as “Jaktinib Hydrochloride Tablets”, “Jaktinib” and “Jaktinib hydrochloride tablets”.

Its studies are mostly in Primary Myelofibrosis · Dermatitis, Atopic · Alopecia Areata · Spondylitis, Ankylosing · COVID-19, led by Suzhou Zelgen Biopharmaceuticals.

Furthest: phase 3, since Oct 26, 202031 company-led studies, 8 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Zelgen Biopharmaceuticals318 open or runningphase 3since Oct 26, 2020Mar 20, 2019Feb 2027phase 1 · NCT07565597

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Mar 20, 2019.

  1. Jul 23, 2021Phase 1 study in Hepatic InsufficiencyNCT04993404 · 24 enrolled · China
  2. Sep 11, 2021Phase 3 study in Alopecia AreataNCT05051761 · 425 enrolled · China
  3. Nov 24, 2021Phase 1 study in Healthy Adult Male VolunteersNCT05150717 · 6 enrolled · China
  4. Feb 11, 2022Phase 3 study in Alopecia AreataNCT05255237 · 315 enrolled · China
  5. Mar 2, 2022Phase 1 study in Primary MyelofibrosisNCT05279001 · 26 planned · United States
  6. Aug 25, 2022Phase 3 study in Dermatitis, AtopicNCT05526222 · 443 enrolled · China
  7. Dec 30, 2022Phase 3 study in Dermatitis, AtopicNCT05676242 · 207 enrolled · China
  8. Jan 8, 20233 phase 2 studiesNCT05686629, NCT05688839, NCT05702788
  9. May 6, 20232 phase 3 studies in Spondylitis, AnkylosingNCT05861128, NCT05861102
  10. Nov 9, 2023Phase 1 study in Primary MyelofibrosisNCT06132243 · 52 enrolled · China
  11. Dec 20, 2023Phase 1 study in Healthy ParticipantsNCT06193148 · 32 enrolled · China
  12. Jan 30, 2024Phase 1 study in Healthy VolunteersNCT06246695 · 40 enrolled · China
  13. Mar 13, 20252 phase 2 studiesNCT06883526, NCT06903377
  14. Apr 27, 2026Phase 1 study in HealthyNCT07565597 · 64 enrolled · China

Ahead

  1. Feb 2027Primary completion: phase 1 study in HealthyNCT07565597
  2. Apr 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06903377
  3. Apr 2027Primary completion: phase 2 study in LymphomaNCT06883526

TargetBeta

“Jaktinib is a broad-spectrum kinase inhibitor that targets non-receptor tyrosine Janus-associated kinases (JAK1, JAK2, JAK3, and TYK2), as well as FLT3 (FMS-like tyrosine kinase 3) and c-Kit.”study text, by rule · the study

Studies

All 31 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07565597Healthy · China1Active, not recruitingFeb 202764
NCT06903377Carcinoma, Non-Small-Cell Lung · China2RecruitingApr 202750
NCT06883526Lymphoma · China2RecruitingApr 202760
NCT06246695Healthy Volunteers · China1CompletedJan 12, 202240
NCT06193148Healthy Participants · China1CompletedJun 18, 202432
NCT06132243Primary Myelofibrosis · China1CompletedDec 20, 202352
NCT05861128Spondylitis, Ankylosing · China3CompletedMar 4, 2026207
NCT05861102Spondylitis, Ankylosing · China3CompletedJun 9, 2025265
NCT05702788COVID-192WithdrawnApr 23, 20240
NCT05688839Novel COVID-19-Infected Pneumonia · China2Not yet recruitingFeb 202560
NCT05686629Novel COVID-19-Infected Pneumonia · China2Not yet recruitingFeb 2025120
NCT05676242Dermatitis, Atopic · China3CompletedMar 12, 2026207
NCT05526222Dermatitis, Atopic · China3CompletedAug 5, 2025443
NCT05279001Primary Myelofibrosis · United States1RecruitingMay 31, 202526
NCT05255237Alopecia Areata · China3CompletedJun 28, 2024315
NCT05150717Healthy Adult Male Volunteers · China1CompletedJan 30, 20226
NCT05051761Alopecia Areata · China3CompletedDec 27, 2023425
NCT04993404Hepatic Insufficiency · China1CompletedSep 19, 202224
NCT04971551Acute Graft-Versus-Host Disease · China2Not yet recruitingJun 202560
NCT04866056Myelodysplastic Syndromes · China2TerminatedJun 10, 20221
NCT04851535Primary Myelofibrosis · China2CompletedNov 1, 202234
NCT04612699Moderate-to-Severe Plaque Psoriasis · China2CompletedAug 15, 2022123
NCT04617028Primary Myelofibrosis · China3CompletedOct 18, 2023105
NCT04539639Dermatitis, Atopic · China2CompletedMay 19, 2022166
NCT04507659Spondylitis, Ankylosing · China2CompletedAug 2, 2022108
NCT04445363Alopecia Areata · China2Active, not recruitingDec 1, 2024160
NCT04435392Dermatitis, Atopic · China2CompletedSep 8, 2022107
NCT04312594Idiopathic Pulmonary Fibrosis · China2CompletedJun 9, 202291
NCT04217993Primary Myelofibrosis · China2CompletedAug 3, 202251
NCT04034134Alopecia Areata · China2CompletedNov 26, 2021111
NCT03886415Primary Myelofibrosis · China2CompletedFeb 2, 2021118

How it is read

Names in the registry

  • “Jaktinib Hydrochloride Tablets”, 12 entries
  • “Jaktinib”, 11 entries
  • “Jaktinib hydrochloride tablets”, 6 entries
  • “Jaktinib Hydrochloride Tablet”, 3 entries
  • “Gecacitinib Hydrochloride Tablets”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.